Frontiers | A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Novel Methodology for Rapid Detection of KRAS Mutation Using PNA-LNA Mediated Loop-Mediated Isothermal Amplification | PLOS ONE
Addgene: pDNA2.0-6H-TEV-KRAS G12D
Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity
Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acid‑based antisense: A potential new drug candidate for pancreatic cancer
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Oncogenic G12D mutation alters local conformations and dynamics of K-Ras | Scientific Reports
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond - ScienceDirect
Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations
Addgene: pHAGE-KRAS-G12D Sequences
KRAS Protein Overview: Sequence, Structure, Function and Protein Interaction | Sino Biological
KRAS - Wikipedia
Exploiting TCR affinity for therapeutic targeting of neoantigens
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach | PLOS ONE
Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles | Journal of Proteome Research
RCSB PDB - 6GOF: KRAS full length G12D GPPNHP
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA | ACS Pharmacology & Translational Science
Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells | Scientific Reports
Frontiers | KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Silencing of oncogenic KRAS by mutant-selective small interfering RNA Bjoern Papke1, Salma H. Azam1,2, Anne Y. Feng1, Amanda E.
JCM | Free Full-Text | Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo | Scientific Reports
An in vivo KRAS allelic series reveals distinct phenotypes of common oncogenic variants | bioRxiv
